Evidence map›Paper›PMID 39284668›Full record

ReviewCold Spring Harbor perspectives in medicine2025

Technologies for Decoding Cancer Metabolism with Spatial Resolution.

Walter W Chen, Michael E Pacold, David M Sabatini, Naama Kanarek

Abstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Walter W ChenDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Michael E PacoldDepartment of Radiation Oncology and Perlmutter Cancer Center, NYU Langone Health, New York, New York 10016, USA.
David M SabatiniInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 16610 Prague, Czech Republic.
Naama KanarekDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA naama.kanarek@childrens.harvard.edu.ORCID 0000-0002-2068-3908

Funding

Regulation of the mTOR Pathway By NutrientsR01CA103866 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI WEISSMAN, JONATHAN S. · 2004 to 2021
$7.0M
Cell Growth Signaling in Cancer DevelopmentR01CA129105 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI WEISSMAN, JONATHAN S. · 2008 to 2021
$5.9M
TRANSLATIONAL CONTROL BY RAPAMYCIN-SENSITIVE SIGNALINGR01AI047389 · NIAID · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI WEISSMAN, JONATHAN S. · 2000 to 2021
$4.9M
Mechanistic Study of Methotrexate-Induced Oxidative Distress in Neurons and the CSFR01CA282477 · NCI · BOSTON CHILDREN'S HOSPITAL · PI Naama Kanarek · 2024 to 2026
$3.5M
Mechanisms Promoting Copper Dependent Cell Death in CancerR01CA279550 · NCI · BROAD INSTITUTE, INC. · PI Sandro Santagata, Peter Tsvetkov · 2023 to 2026
$2.4M
Cellular Adaptations to Nutrient-Limited Metabolic MicroenvironmentsR35GM147119 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Michael Edward Pacold · 2022 to 2026
$2.1M
NCI NIH HHS R01 CA103866NCI NIH HHS R01 CA129105NCI NIH HHS R01 CA279550NCI NIH HHS R01 CA282477NIAID NIH HHS R01 AI047389NIGMS NIH HHS R35 GM147119
6 · The paper itself

Abstract

It is increasingly appreciated that cancer cells adapt their metabolic pathways to support rapid growth and proliferation as well as survival, often even under the poor nutrient conditions that characterize some tumors. Cancer cells can also rewire their metabolism to circumvent chemotherapeutics that inhibit core metabolic pathways, such as nucleotide synthesis. A critical approach to the study of cancer metabolism is metabolite profiling (metabolomics), the set of technologies, usually based on mass spectrometry, that allow for the detection and quantification of metabolites in cancer cells and their environments. Metabolomics is a burgeoning field, driven by technological innovations in mass spectrometers, as well as novel approaches to isolate cells, subcellular compartments, and rare fluids, such as the interstitial fluid of tumors. Here, we discuss three emerging metabolomic technologies: spatial metabolomics, single-cell metabolomics, and organellar metabolomics. The use of these technologies along with more established profiling methods, like single-cell transcriptomics and proteomics, is likely to underlie new discoveries and questions in cancer research.

Indexed as

MetabolomicsNeoplasmsHumansMass SpectrometrySingle-Cell Analysis

Identifiers

PMID39284668
PMCPMC12211997

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.